Abbvie Inc
NYSE:ABBV

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
NYSE:ABBV
Watchlist
Price: 171.73 USD 2.37% Market Closed
Market Cap: 303.5B USD
Have any thoughts about
Abbvie Inc?
Write Note

Intrinsic Value

The intrinsic value of one ABBV stock under the Base Case scenario is 140.4 USD. Compared to the current market price of 171.73 USD, Abbvie Inc is Overvalued by 18%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ABBV Intrinsic Value
140.4 USD
Overvaluation 18%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Abbvie Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ABBV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ABBV?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Abbvie Inc

Provide an overview of the primary business activities
of Abbvie Inc.

What unique competitive advantages
does Abbvie Inc hold over its rivals?

What risks and challenges
does Abbvie Inc face in the near future?

Has there been any significant insider trading activity
in Abbvie Inc recently?

Summarize the latest earnings call
of Abbvie Inc.

What significant events have occurred
in Abbvie Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Abbvie Inc.

Provide P/S
for Abbvie Inc.

Provide P/E
for Abbvie Inc.

Provide P/OCF
for Abbvie Inc.

Provide P/FCFE
for Abbvie Inc.

Provide P/B
for Abbvie Inc.

Provide EV/S
for Abbvie Inc.

Provide EV/GP
for Abbvie Inc.

Provide EV/EBITDA
for Abbvie Inc.

Provide EV/EBIT
for Abbvie Inc.

Provide EV/OCF
for Abbvie Inc.

Provide EV/FCFF
for Abbvie Inc.

Provide EV/IC
for Abbvie Inc.

Show me price targets
for Abbvie Inc made by professional analysts.

What are the Revenue projections
for Abbvie Inc?

How accurate were the past Revenue estimates
for Abbvie Inc?

What are the Net Income projections
for Abbvie Inc?

How accurate were the past Net Income estimates
for Abbvie Inc?

What are the EPS projections
for Abbvie Inc?

How accurate were the past EPS estimates
for Abbvie Inc?

What are the EBIT projections
for Abbvie Inc?

How accurate were the past EBIT estimates
for Abbvie Inc?

Compare the revenue forecasts
for Abbvie Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Abbvie Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Abbvie Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Abbvie Inc compared to its peers.

Compare the P/E ratios
of Abbvie Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Abbvie Inc with its peers.

Analyze the financial leverage
of Abbvie Inc compared to its main competitors.

Show all profitability ratios
for Abbvie Inc.

Provide ROE
for Abbvie Inc.

Provide ROA
for Abbvie Inc.

Provide ROIC
for Abbvie Inc.

Provide ROCE
for Abbvie Inc.

Provide Gross Margin
for Abbvie Inc.

Provide Operating Margin
for Abbvie Inc.

Provide Net Margin
for Abbvie Inc.

Provide FCF Margin
for Abbvie Inc.

Show all solvency ratios
for Abbvie Inc.

Provide D/E Ratio
for Abbvie Inc.

Provide D/A Ratio
for Abbvie Inc.

Provide Interest Coverage Ratio
for Abbvie Inc.

Provide Altman Z-Score Ratio
for Abbvie Inc.

Provide Quick Ratio
for Abbvie Inc.

Provide Current Ratio
for Abbvie Inc.

Provide Cash Ratio
for Abbvie Inc.

What is the historical Revenue growth
over the last 5 years for Abbvie Inc?

What is the historical Net Income growth
over the last 5 years for Abbvie Inc?

What is the current Free Cash Flow
of Abbvie Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Abbvie Inc.

Business Breakdown

AbbVie Inc. is a global biopharmaceutical company that emerged from Abbott Laboratories in 2013, establishing itself as a key player in the healthcare sector with a strong focus on developing innovative therapies. Headquartered in North Chicago, Illinois, AbbVie specializes in immunology, oncology, neuroscience, and virology, boasting a diverse portfolio of products designed to address complex health challenges. Its flagship drug, Humira, has been a cornerstone of the company’s success, contributing significantly to its revenues since it was launched. However, with the expiration of Humira's patent, AbbVie is strategically transitioning its focus toward new treatments, including promising dr...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Abbvie Inc

Current Assets 27.8B
Cash & Short-Term Investments 7.3B
Receivables 11.5B
Other Current Assets 9B
Non-Current Assets 115.6B
Long-Term Investments 267m
PP&E 5.1B
Intangibles 101.9B
Other Non-Current Assets 8.3B
Current Liabilities 43.1B
Accounts Payable 30.5B
Other Current Liabilities 12.6B
Non-Current Liabilities 94.3B
Long-Term Debt 58.5B
Other Non-Current Liabilities 35.8B
Efficiency

Earnings Waterfall
Abbvie Inc

Revenue
55.5B USD
Cost of Revenue
-18.2B USD
Gross Profit
37.3B USD
Operating Expenses
-21.9B USD
Operating Income
15.4B USD
Other Expenses
-10.4B USD
Net Income
5.1B USD

Free Cash Flow Analysis
Abbvie Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the third quarter, AbbVie reported nearly $14.5 billion in revenue, a 4.9% operational increase, with adjusted EPS of $3, beating guidance. Their ex-HUMIRA portfolio thrived, driven by SKYRIZI and RINVOQ, expected to exceed $17 billion in sales this year. They raised full-year adjusted EPS guidance to $10.90-$10.94 and total revenue to approximately $56 billion. HUMIRA faced a 36.5% decline, but its erosion positively impacted new drug sales. The recent acquisition of Cerevel Therapeutics enhances their neuroscience pipeline. Overall, AbbVie maintains strong growth prospects with solid cash flow supporting a 5.8% dividend increase starting in 2025.

What is Earnings Call?
Fundamental Scores

ABBV Profitability Score
Profitability Due Diligence

Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Gross Profit
Exceptional ROE
72/100
Profitability
Score

Abbvie Inc's profitability score is 72/100. The higher the profitability score, the more profitable the company is.

ABBV Solvency Score
Solvency Due Diligence

Abbvie Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
Positive Net Debt
34/100
Solvency
Score

Abbvie Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABBV Price Targets Summary
Abbvie Inc

Wall Street analysts forecast ABBV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABBV is 210.28 USD with a low forecast of 166.65 USD and a high forecast of 252 USD.

Lowest
Price Target
166.65 USD
3% Downside
Average
Price Target
210.28 USD
22% Upside
Highest
Price Target
252 USD
47% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ABBV?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Previous Payment
-
Today
Next Payment
-
Today
Nov 22, 2024
Previous Payment
-
Next Payment
-
Ex-Dividend Date
-
Shareholder Yield

Current shareholder yield for ABBV is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ABBV Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ABBV News

Other Videos

Profile

Abbvie Inc Logo
Abbvie Inc

Country

United States of America

Industry

Biotechnology

Market Cap

303.5B USD

Dividend Yield

3.61%

Description

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products include Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The firm's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Contact

ILLINOIS
North Chicago
1 N Waukegan Rd
+18479327900.0
www.abbvie.com

IPO

2013-01-02

Employees

50 000

Officers

Executive Chairman
Mr. Richard A. Gonzalez
CEO & Director
Mr. Robert A. Michael
Executive VP & CFO
Mr. Scott T. Reents
Executive VP & COO
Dr. Azita Saleki-Gerhardt Ph.D.
Executive VP & Chief Commercial Officer
Mr. Jeffrey Ryan Stewart
Executive VP of Research and Development & Chief Scientific Officer
Dr. Roopal Thakkar M.D.
Show More
Senior Vice President of Investor Relations
Ms. Elizabeth Shea
Executive VP, General Counsel & Secretary
Mr. Perry C. Siatis
Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Mr. Sanjay Narayan
Executive VP & Chief Human Resources Officer
Mr. Timothy J. Richmond
Show Less

See Also

Discover More
What is the Intrinsic Value of one ABBV stock?

The intrinsic value of one ABBV stock under the Base Case scenario is 140.4 USD.

Is ABBV stock undervalued or overvalued?

Compared to the current market price of 171.73 USD, Abbvie Inc is Overvalued by 18%.

Back to Top